One more step

Please complete the security check to access api.p-treff.info

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

What can I do to prevent this in the future?

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Attention Required! | Cloudflare

One more step

Please complete the security check to access api.p-treff.info

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

What can I do to prevent this in the future?

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Attention Required! | Cloudflare

One more step

Please complete the security check to access api.p-treff.info

Why do I have to complete a CAPTCHA?

table

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

What can I do to prevent this in the future?

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Attention Required! | Cloudflare

One more step

Please complete the security check to access api.p-treff.info

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

What can I do to prevent this in the future?

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

HealthEconomics.Com https://www.healtheconomics.com Health Outcomes, Market Access, and HEOR Global News Resources and Jobs. Sun, 15 Sep 2019 17:03:26 +0000 en-US hourly 1 https://wordpress.org/?v=5.2.3 Article Considers International Pricing Index for More than Part B Drugs https://www.healtheconomics.com/government/article-considers-international-pricing-index-for-more-than-part-b-drugs Sun, 15 Sep 2019 17:03:26 +0000 https://www.healtheconomics.com/?p=103980

While the Trump administration is exploring an international pricing index for Medicare Part B drugs, the U.S. appears to pay more for Part D drugs than other countries, the authors of a recent Health Affairs blog post write.

“While international drug price comparisons are challenging, two studies published in Health Affairs suggest that net drug prices in Part D and systemwide in the US are significantly higher than in other wealthy countries,” they write.

The authors look at what it would mean to expand an international pricing model to Medicare Part D and Medicaid, including some possible roadblocks.

To read the full post, click here.

]]>
Should the U.S. Government Get More Involved in Drug Prices? https://www.healtheconomics.com/uncategorized/should-the-u-s-government-get-more-involved-in-drug-prices Sun, 15 Sep 2019 16:43:28 +0000 https://www.healtheconomics.com/?p=103977

The U.S. government should look to other economically developed countries with a heavier hand in drug pricing in order to better wrangle drug prices, the authors of a recent article published on The Conversation write.

More government involvement in drug prices, however, has gained “little favor” in the U.S., the authors write.

“Many countries with universal health care or multipayer systems, or both, have national organizations responsible for conducting health technology assessments,” they write. “These generate evidence to support reimbursement decisions and price setting. Countries that do this include Australia, Canada, Germany, Ireland and the United Kingdom.”

To read the full article, click here.

 

]]>
FDA’s Woodcock Outlines Problem Areas of Medical Innovation https://www.healtheconomics.com/government/fdas-woodcock-outlines-problem-areas-of-medical-innovation Sat, 14 Sep 2019 14:51:34 +0000 https://www.healtheconomics.com/?p=103975

Janet Woodcock, director of the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, had a blunt message for a crowd of roughly 150 researchers on the state of medical innovation in the U.S., according to a Los Angeles Times report: “It’s not working, and it won’t work in the future.”

Woodcock during the Breakthroughs in Medicine conference Friday said the goal extends beyond “improving knowledge” and getting the green light from the FDA, it’s “to improve human health.”

“Is the guy living under the bridge going to get a $2-million CAR-T cell curative therapy?” she asked.

To read the full report, click here.

]]>
Warren Adds Drug Pricing to Campaign https://www.healtheconomics.com/government/warren-adds-drug-pricing-to-campaign Sat, 14 Sep 2019 14:24:19 +0000 https://www.healtheconomics.com/?p=103973

Democratic Sen. Elizabeth Warren added a health care plan to her presidential campaign, as well as policies to wrangle drug prices, hours before the Sept. 12 presidential debate, InsideHealthPolicy reports.

According to the report, the proposed bill, the Affordable Drug Manufacturing Act, would require the government to create generic drugs when the prices of brand drugs surge.

To read the full report, click here.

]]>
Article Looks at How Drugs Are Priced https://www.healtheconomics.com/industry-news/article-looks-at-how-drugs-are-priced Fri, 13 Sep 2019 14:52:44 +0000 https://www.healtheconomics.com/?p=103968

A recent report by Investor’s Business Daily spotlights how pharmaceutical companies put a price tag on their drugs.

According to the report, drugmakers in the first half of this year rolled out price increases on 3,400 drugs by an average of 10.5 percent, five times the rate of inflation.

“Drug prices are just the most visible part of multiple different broken systems in health care,” Stanford University Graduate School of Business Professor of Medicine and Economics Kevin Schulman said. “Unfortunately, what we have in health care is, across the board, these incredibly nontransparent markets that are designed that way. Because no one in their right mind would agree to the way we pay for drugs, medical care or surgical care and the prices that are being charged.”

To read the full report, click here.

]]>
States Taking Action on Drug Prices https://www.healtheconomics.com/government/states-taking-action-on-drug-prices Fri, 13 Sep 2019 14:10:50 +0000 https://www.healtheconomics.com/?p=103966

Thirty-three states so far this year have passed a record 51 laws to address rising drug prices and affordability, Kaiser Health News reports.

According to the report, 28 states passed 45 laws in 2018.

“Legislative activity in this area is escalating,” Trish Riley, National Academy for State Health Policy executive director, tells KHN. “This year, some states moved to launch programs that directly impact what they and consumers pay for high-cost drugs.”

To read the full report on KHN, click here.

]]>
Report: Novo Nordisk Slashing U.S. Insulin Prices https://www.healtheconomics.com/industry-news/report-novo-nordisk-slashing-u-s-insulin-prices Fri, 13 Sep 2019 14:05:53 +0000 https://www.healtheconomics.com/?p=103964

Danish drugmaker Novo Nordisk announced its plans to cut the prices of insulin in the U.S. amid rising criticism over the treatment’s high prices, Reuters reports.

According to the report, the drugmaker will offer a generic version of Novolog, an insulin drug used by roughly one million patients in the U.S., at a 50 percent discount. One vial will carry a $144.68 price tag.

“While we will continue to do what we can to help address affordability challenges in the short-term, changes within the system are required to make sustainable and meaningful affordability a reality,” Novo Nordisk said in a statement.

To read the full report on Reuters, click here.

]]>
Germany as a Model for Drug Pricing Solutions? https://www.healtheconomics.com/government/germany-as-a-model-for-drug-pricing-solutions Thu, 12 Sep 2019 15:31:36 +0000 https://www.healtheconomics.com/?p=103960

With American policymakers working to find solutions to rising drug prices, Germany’s model could hold some clues, the author of a recent article published on Harvard Business School’s Working Knowledge writes.

Germany since 2011 has required pharmaceutical companies justify high price tags for drugs that have cheaper competitors, the author writes.

“The implication for German health insurers — and indirectly, consumers — has been millions of euros in savings on drug spending, without any evidence so far of compromised access to the most valuable new drugs,” Ariel Stern, Poronui associate professor of business administration, said.

To read the full article, click here.

]]>
Makary Discusses Health Care, New Book on Relentless Health Value Podcast https://www.healtheconomics.com/industry-news/makary-discusses-health-care-new-book-on-relentless-health-value-podcast Thu, 12 Sep 2019 15:21:10 +0000 https://www.healtheconomics.com/?p=103958

A new Relentless Health Value podcast features Dr. Martin Makary to discuss his new book, “The Price We Pay: What Broke American Health Care — and How to Fix It.”

Makary, a surgeon, is both a New York Times best-selling author and Johns Hopkins health policy expert.

“I could not recommend this book more highly,” a description of the podcast states. “It’s a page turner for hospital execs trying to do the right thing, employers trying to do right by their employees, insurance carriers looking for better ways to actually drive health care value, and doctors and nurses who are feeling burnout because they see their organizations demanding them to do things misaligned with their mission to do the best they can by patients.”

To listen to the podcast on Relentless Health Value, click here.

]]>
ISPOR Announces New Short Courses in Copenhagen https://www.healtheconomics.com/industry-news/ispor-announces-new-short-courses-in-copenhagen Thu, 12 Sep 2019 15:15:00 +0000 https://www.healtheconomics.com/?p=103956

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced nine new short courses slated for its upcoming meeting in Copenhagen, Denmark, set to kick off Saturday, Nov. 2.

ISPOR in an email says the courses “cover the latest hot topics in the field and were developed by global experts.”

The nine courses are:

  • US Payers—Understanding the Healthcare System
  • Fitting the Structure to the Task- Choosing the Right Dynamic Simulation Model to Inform Decisions about Healthcare Delivery
  • Health State Utility (HSU) Recommendations for Identification and Use of HSU Data in Cost-Effectiveness Modeling
  • Why All the Hype? Nordic Data Explained
  • Digital Real-World Evidence Generation Approaches in Rare Diseases and Oncology
  • Market Access & Value Assessment of Medical Devices
  • Probabilistic Graphical Models with OpenMarkov, an Open-Source Tool
  • Creating Natural, Flexible Models with DICE Simulation
  • Mapping to Estimate Utility Values from Non-Preference-Based Outcome Measures—Part 2

To learn more, click here.

Click here to learn more about the upcoming event in Copenhagen, Denmark.

]]>